Promega has partnered with EditCo Bio, a leader in engineered cell solutions, offering high-quality, functionally validated CRISPR-edited cell lines, the company announced recently.

“This agreement accelerates scientific innovation by providing researchers with advanced cellular models engineered for precise functional analysis,” Promega Vice President of Life Sciences Tom Livelli said in a statement. “Leveraging these technologies enables scientists to probe protein dynamics directly within living cells, empowering deeper insights into complex biological mechanisms.”

According to a release, EditCo Bio, located in Redwood City, Calif., will incorporate Promega’s proprietary bioluminescent and protein-labeling technologies into its CRISPR-engineered cell lines, ensuring precise gene edits with functional validation.

Financial terms were not disclosed.